Construction & cities

Kazakhstan: Biopharmaceutical Complex in Alatau Approved for ₸103 Billion

Investors, volumes and stages of the region's major projects – for European suppliers

· 3 Sources

Scroll
Construction & cities Kazakhstan3 Sources

Published · last updated · 1 Jan 2026

The government of Kazakhstan has approved an investment agreement for the construction of a biopharmaceutical complex in the Alatau Special Economic Zone. The project by Khan Tengri Biopharma involves the production of 58 types of medicines and aims to reduce dependency on imports.

Approval and Investment Framework

Prime Minister Olzhas Bektenov has signed a resolution approving an investment agreement between the Ministry of Healthcare of the Republic of Kazakhstan and Khan Tengri Biopharma LLP. The project implements presidential instructions to increase the share of domestic pharmaceutical production to 50 percent. The total investment volume exceeds ₸103 billion.

Production and Location

The complex will be built in the Alatau Special Economic Zone, providing access to infrastructure, tax preferences, and logistics. The company plans to produce 58 types of medicines, including 27 international nonproprietary names (INNs). The focus is on complex and expensive categories, particularly for oncological, autoimmune, rare, and inflammatory diseases. A key feature is the establishment of a full production cycle, including the manufacturing of active pharmaceutical ingredients (APIs).

Economic Impact and Export

The project will create more than 180 new permanent jobs. The goal is to reduce dependency on drug imports and stabilize prices for socially significant medications. Part of the production is intended for export to the markets of the Commonwealth of Independent States (CIS), the Eurasian Economic Union (EAEU), and countries in the Middle East. Implementation aims to develop local competencies and a technological base within the industry.

Project: Alatau Biopharmaceutical Complex · Kazakhstan · Agreed

Key facts

  • Investment volume: more than ₸103 billion
  • Location: Alatau Special Economic Zone, Kazakhstan
  • Developer: Khan Tengri Biopharma LLP
  • Jobs: more than 180 permanent positions
  • Production: 58 medicine types, 27 international nonproprietary names
  • Goal: Increase domestic production to 50 percent

All sources (4)

  1. Биофарма в Казахстане: новый завод на ₸103 млрд - что это даст странеDKNews.kz · · RU
  2. Биофармацевтический комплекс построят в Казахстане за ₸103 млрдKursiv Media · · RU
  3. Биофармацевтический комплекс полного цикла на ₸103 млрд построят в КазахстанеPrimeMinister.kz · · RU
  4. Full-Cycle Biopharmaceutical Complex Worth 103 Billion Teenge to Be Built in KazakhstanPrimeMinister.kz · · EN

Imprint | Information pursuant to § 5 DDG

Company

AETEK GmbH Lindenstraße 5
63808 Haibach, Germany

Managing Director

Artur R. Pamin

Commercial Register

Amtsgericht Aschaffenburg
HRB 14157

VAT ID No.

DE288091462

EORI No.

DE644795536634916

Scan · LinkedIn